Renata Gontijo Lima
Eli Lilly (United States)(US)University of Lübeck(DE)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Psoriasis: Treatment and Pathogenesis, Asthma and respiratory diseases, Food Allergy and Anaphylaxis Research, Allergic Rhinitis and Sensitization
Most-Cited Works
- → Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis(2023)280 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis(2023)127 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*(2020)112 cited
- → Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )(2020)106 cited
- → Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study(2023)37 cited
- → PREVALENCE OF ASTHMA, RHINITIS AND ECZEMA IN 6 - 7 YEARS OLD STUDENTS FROM THE WESTERN DISTRICTS OF SÃO PAULO CITY, USING THE STANDARDIZED QUESTIONNAIRE OF THE “INTERNATIONAL STUDY OF ASTHMA AND ALLERGIES IN CHILDHOOD” (ISAAC)-PHASE IIIB(2007)29 cited
- → 14152 Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate to severe plaque psoriasis(2020)4 cited
- Psoríase e comorbidades(2011)
- → A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis(2020)1 cited